Anti-HIV effects of Viracept persist during long periods of combination therapy.
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D004279:DNA, Viral / Q000032:analysis / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006678:HIV / Q000187:drug effects* / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D019888:Nelfinavir; D012449:Safety; D013451:Sulfonic Acids / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D004279:DNA, Viral; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D013451:Sulfonic Acids; D019888:Nelfinavir